|
|
|
|
| LEADER |
01603nam a2200253 u 4500 |
| 001 |
EB002001235 |
| 003 |
EBX01000000000000001164136 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Shalev, Noga
|
| 245 |
0 |
0 |
|a Laboratory monitoring for adverse effects of ART
|h Elektronische Ressource
|c lead author, Noga Shalev, with the Medical Care Criteria Committee
|
| 246 |
3 |
1 |
|a Medical Care Criteria Committee
|
| 260 |
|
|
|a Baltimore (MD)
|b Johns Hopkins University
|c September 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (6 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a New York (State)
|b AIDS Institute
|
| 710 |
2 |
|
|a Johns Hopkins University
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 500 |
|
|
|a At head of title: "Clinical Guidelines Program, New York State, Department of Health, AIDS Institute."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK558200
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This guideline was developed by the New York State Department of Health AIDS Institute to establish an evidence-based approach to routine laboratory monitoring of antiretroviral toxicity. Data are lacking regarding the need for and frequency of routine laboratory monitoring in patients receiving antiretroviral therapy (ART). To date, no randomized controlled studies have assessed the optimal type and frequency of monitoring. The data available are based on short-term randomized clinical trials of ART strategies, observational cohort data, and long-term epidemiologic data
|